Endocare Repair Efficacy Skincare Products in the Use of Post-laser Treatment
A Single-center, Prospective, Randomized, Double-blind, Self-controlled Clinical Study Evaluating the Efficacy and Safety of Endocare Repairing Skincare Product in Skin Recovery After Ablative Fractional Laser Treatment .
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200040
- Huashan Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Individuals aged 30-65 years;
- Candidates for ablative fractional laser treatment on the face;
- Agree to undergo photographic documentation before and after the ablative fractional laser procedure and during follow-up visits;
- Refrain from using other similar products (except facial cleansers) after ablative fractional laser treatment;
- Written informed consent obtained.
Exclusion Criteria:
- known hypersensitivity to product ingredients;
- active skin infections;
- history of keloid formation;
- immunosuppressive therapy and pregnancy or lactation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: SCA Side
One half of the face received the active product contained 40% secretion of SCA
|
One half of the face received the active product contained 40% secretion of SCA covering all lasered areas.
|
|
Placebo Comparator: Placebo Side
The other half received an identical-appearing placebo cream (a basic moisturizer containing no SCA ingredients
|
The other half received an identical-appearing placebo cream (a basic moisturizer containing no SCA ingredients, but otherwise matching the active product in appearance and texture), covering all lasered areas.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Microcolumn Density Under Dermoscopy
Time Frame: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28
|
The primary outcome was the rate of re-epithelialization, assessed by the density of visible microcolumns which was examined using the Medicam®1000 dermoscopy system.
This measure was complemented by a clinical healing score (0-3 scale for each side, where 0 = fully healed skin, 1 = fine pinpoint scaling, 2 = visible micro-crusts, 3 = obvious unhealed areas) assigned by a blinded dermatologist.
|
Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Transepidermal Water Loss (TEWL)
Time Frame: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28
|
Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28
|
|
|
Melanin Index (MI)
Time Frame: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28
|
MI can detect pigment changes, allowing assessment of any PIH or other dyschromia resulting from the laser or differential healing.
Higher MI indicates a prolonged post-laser reaction.
|
Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28
|
|
Erythema Index (EI)
Time Frame: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28.
|
EI quantifies redness to track the resolution of laser-induced erythema.
Higher EI indicates a prolonged post-laser reaction.
|
Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28.
|
|
Investigator Global Assessment (IGA)
Time Frame: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28
|
Key symptoms including erythema, edema, crusting, exudation and crusting were graded (with a score from 0-3) by the investigator at each visits. Erythema: 0 - No redness
Edema: 0 - No edema
Exudation: 0 - No exudation
Crusting: 0 - No crusting
|
Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28
|
|
Patient Self-Assessments (PGA)
Time Frame: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28.
|
Patients rated tightness and burning in a scale of 0-3.
0=none, 1=mild, 2=moderate, 3=severe.
|
Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28.
|
|
Visual Analog Scale (VAS)
Time Frame: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28.
|
Assessed immediately after treatment and at follow-up visits using a 0-10 VAS score.
10 being the highest pain.
|
Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2022-554
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.